Origin BioMed in Receivership
Origin BioMed has been placed in receivership.
The Chronicle-Herald reported Friday that the Halifax company was placed in receivership on March 16, with Grant Thornton Ltd. being appointed trustee.
Origin Biomed, which had received venture capital funding from Nova Scotia Business Inc., GrowthWorks Atlantic and Avrio Ventures of Calgary, manufactured and marketed Neuragen, a natural pain relief for diabetes sufferers.
At its height, the company sold the sold the product over-the-counter at more than 20,000 stores in the U.S. and Canada. However, in 2011 the company ran into problems